Remove 2030 Remove Disease Remove Pharmaceuticals
article thumbnail

Treatment potential for immunotherapy-induced cytokine release syndrome  

Drug Discovery World

Poolbeg Pharma, a biopharmaceutical company focused on the development and commercialisation of medicines targeting diseases with a high unmet medical need, has announced promising in vivo results for POLB 001 in addressing cancer immunotherapy-induced cytokine release syndrome (CRS). million cases of cancer by 2030 1,2.

Treatment 162
article thumbnail

This week in drug discovery (10-14 April)

Drug Discovery World

The headlines our attention this week all represent significant breakthroughs in the treatment of various diseases and could make a huge difference to the lives of these patients. There is also new hope for sepsis treatment and for preventing cardiovascular disease in people with HIV thanks to recent research.

Vaccine 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

UK announces £210 million fund to tackle antimicrobial resistance

Drug Discovery World

The money is intended to pay for new laboratories, disease surveillance systems, and a bigger global workforce. The pharmaceutical industry has also stepped up support and invested £1.2 billion to bring new antibiotics to market by 2030 through the AMR Action Fund.

article thumbnail

Europe: Where is the drug discovery innovation?

Drug Discovery World

Europe is traditionally a life sciences powerhouse, with a strong tradition in pharmaceutical discovery. The oldest, still active pharmaceutical company worldwide, Merck, started life in 1668 in Darmstadt, Germany. Members of the European Federation of Pharmaceutical Industries and Associations (EFPIA) spent €41.5 billion ($7.9

Drugs 147
article thumbnail

Phase Ib/IIa trial in diabetic macular oedema successfully completed  

Drug Discovery World

Exonate has now regained full rights to its complete portfolio of ophthalmology assets from Janssen Pharmaceuticals EXN407 is reportedly well placed to be the first topical treatment for retinal vascular diseases, including diabetic retinopathy and diabetic macular oedema. Coupled with a large and growing market (US$8.3

article thumbnail

Pharma’s important climate

Drug Discovery World

Worryingly, according to the United Nations, national climate plans for parties to the Paris Agreement would bring us back to 2010 emission levels, leading to a rise of around 11% in greenhouse gases by 2030. In fact, a 2019 study shows that the pharmaceutical industry generates around 48.55 degrees Celsius.

article thumbnail

Sandoz announces new global ‘Act4Biosimilars’ initiative, to improve patient access and increase adoption by at least 30% in 30+ countries by 2030

The Pharma Data

The initiative is supported by a multidisciplinary Steering Committee of patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders from around the world, with a mission to increase global adoption of biosimilar medicines by at least 30% in 30+ countries by 2030.